<DOC>
	<DOCNO>NCT00690612</DOCNO>
	<brief_summary>The HIP study design follow clinical experience young hypertensive child receive candesartan cilexetil ( Atacand ) age 1 less 11 year old . The study open label concurrent control group . To eligible HIP , child must complete Study 328 without discontinuation due study drug-related AE investigator 's opinion , on-going clinical indication orally administer suspension candesartan cilexetil control blood pressure . Children return clinic every 3 month ( frequently investigator 's discretion ) safety efficacy evaluation . Safety monitor serum chemistry , urinalysis , echocardiograms physical examination specify clinic visit . Blood pressure heart rate measure clinic visit . Study drug administer orally day . Investigators determine efficacious dose ( 0.05 mg/kg ; 0.2 mg/kg ; 0.4 mg/kg ) vist-by-vist basis depend child 's BP response . It anticipate study dose align closely effective anti-hypertensive dose determine Study 328 . If child 's hypertension well-controlled , dose adjustment maximum 0.4mg/kg/day and/or addition antihypertensive medication permit , exception angiotensin receptor blocker . The HIP study offer eligible child two additional year treatment liquid formulation Atacand .</brief_summary>
	<brief_title>Study Characterize Long-term Clinical Experience Atacand Hypertensive Children Ages 1 &lt; 11 Years ( Hypertension Pediatrics )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>Must participate Protocol 328 ( without discontinuation due study drug relate AE ) . Must sign inform consent prior initiate stus dy procedure . Have , opinion investigator , ongoing clinical indication oral liquid formulation candesartan cilexetil control hypertension Weight ≥ 10 kg ≤ 40 kg . Any situation , clinical condition ( clinically significant decline renal function ) laboratory abnormality , opinion investigator sponsor , may interfere subject 's participation study . Estimated glomerular filtration rate ( GFR ) &lt; 30 ml/min/1.73m2 nontransplant patient &lt; 40 ml/min/1.73m2 transplant patient base Schwartz Formula ( Schwartz et al 1987 ) determine enrollment Study 328 . Impaired liver function define either acute liver disease chronic liver disease persistently elevate liver enzyme value judge clinically significant investigator . Currently use medication , opinion investigator could negatively affect subject give together candesartan cilexetil .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>pediatric</keyword>
	<keyword>renal disease</keyword>
	<keyword>high blood pressure</keyword>
</DOC>